ultimate nuclear stack? need more suggestions bruhh
    Technology 8/12/2025

    From the encyclopedia
    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    GT20029 →

    research compound made to degrade androgen receptors in scalp

    RU58841 →

    a potent but unapproved and potentially problematic topical anti-androgen

    At a glance
    In this hair loss treatment regimen post, the primary subjects mentioned are
    💊 Dutasteride (oral)
    💧 Dutasteride (topical)
    💧 GT20029 (topical)
    💧 RU58841 (topical)
    💧 Pyrilutamide (topical)
    Minoxidil (foam)
    💊 Minoxidil (oral)
    Microneedling weekly
    💧 Ketoconazole shampoo (topical)
    the tone is humorous.

    Other terms

    The conversation discusses an extensive hair loss treatment regimen including dutasteride, GT20029, RU58841, pyrilutamide, minoxidil, microneedling, ketoconazole shampoo, and experimental compounds. The user humorously describes their approach as a comprehensive strategy to combat hair loss while maintaining hair growth.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community Ultimate Stack without nuking your gender (you'll go broke)

       86 upvotes 1 year ago
      A hair loss treatment plan includes finasteride, dutasteride, RU58841, pyrilutamide, minoxidil, and microneedling to inhibit DHT and promote hair growth. It also recommends supplements like Reishi and Lion’s Mane mushrooms, and a shampoo with ketoconazole, caffeine, and melatonin.

      community Strategies for Treatment Resistant Androgenic Alopecia

      in Treatment  5 upvotes 4 months ago
      The conversation is about a person experiencing treatment-resistant androgenic alopecia despite using high doses of dutasteride and minoxidil, along with other treatments like microneedling and purilutamide. Suggestions include considering a hair transplant, checking medication authenticity, and exploring other treatments like RU58841 or topical estradiol.

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

       124 upvotes 2 years ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

    Related Research

    6 / 6 results
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
      The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis

      research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis

      March 2025 in “Medicine”
      This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.
      Updates in Treatment for Androgenetic Alopecia

      research Updates in Treatment for Androgenetic Alopecia

      January 2025 in “Annals of Dermatology”
      This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
      Androgens and Androgen Receptor in the Management of Skin Diseases

      research Androgens/Androgen Receptor in the Management of Skin Diseases

      1 citations , January 2022 in “Journal of Biosciences and Medicines”
      This review discusses the roles of androgens and androgen receptor in skin diseases like acne and hirsutism, and highlights the promise of antiandrogen drugs, reporting no new clinical findings.